TSO3 ANNOUNCES FULL EXERCISE OF UNDERWRITERS’ OPTION TO PURCHASE ADDITIONAL UNITS
Quebec City, April 5, 2012 – TSO3 Inc. (TSX: TOS) (“TSO3” or the “Corporation”) an innovator in sterilization technology for medical devices in healthcare settings, today announced that, in relation to the private placement of units on a bought deal basis (the “Offering”) announced earlier this week, the underwriters have exercised their option (the “Underwriters’ Option”) to purchase an additional 900,000 units at a price of CDN$1.30 per unit. TSO3 will receive additional gross proceeds of CDN$1,170,000 from the exercise of the Underwriters’ Option, increasing the total size of the offering to CDN$8,970,000. Closing of the Underwriters’ Option is expected to occur concurrent with the closing of the Offering on or about April 24, 2012.
TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. TSO3 designs products for sterile processing areas in the hospital environment and offers an advantageous replacement solutions to other low temperature sterilization processes currently used in hospitals.
For more information about TSO3, visit the Company’s Web site at www.tso3.com
The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.
The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.
-30-Back to Posts